Top Stories

ABB India won an order to automate Reliance Life Sciences' Nashik facility

Aug 21, 2023

By: BlinkX Research Team

On August 21, ABB India stated in an exchange filing that it had received an order from Reliance Life Sciences (RLS) for the deployment of automation and control solutions for new biosimilars and plasma protein production facilities in Nashik, Maharashtra.

The project's scope includes the entire automation of production processes using ABB's distributed control system (DCS) capability system 800xA. Remote I/O systems, Batch Recipe Management, and MES connectivity are all part of this cutting-edge solution. RLS aims to improve its production processes, fulfill regulatory standards, and raise the quality of its goods by leveraging ABB's innovative technologies.

RLS benefits from the integration of ABB's DCS running on the most recent Windows version. The deployment of this innovative technology reduces the total cost of ownership. Furthermore, the DCS system serves as an integration platform, allowing for real-time monitoring of multiple plant sections and the optimization of maintenance operations. Additionally, the technology will enable faster data connection, minimize wiring, optimize hardware footprint, and accelerate project execution.

The 160-acre Nashik site will host factories for a variety of goods, including plasma proteins, biopharmaceuticals, oncology pharmaceuticals, and vaccines. Given the complexities of large-scale biotechnology production and the need for rigorous adherence to regulatory norms, ABB's System 800xA solution is critical in reducing manufacturing mistakes, maintaining consistent product quality, and providing smooth operator interface and batch management.

In addition to the DCS, RLS will benefit from ABB's modular remote I/O solution, which provides a plug-and-play concept to automation. This solution will allow for speedier commissioning, easier process implementation, and future plant capacity expansion.

Reliance Life Sciences seeks to develop high-quality biosimilars at a low cost by increasing its production facilities.

Source: Media Reports